Last 12 months
Inside the activity.
3 purchase rows · 11 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 3 | 0 |
| Mar 2026 | 0 | 5 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 08, 2022 Filed Jun 10, 2022 16:45 UTC |
PAIGE CHRISTOPHERDirector
|
GrantStock Option (Right to Buy) · Derivative | 17,478 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001127602-22-017247 · form4.xml · derivative · entry 1 PAIGE CHRISTOPHER · CIK 0001742209 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,478 Underlying: Common Stock · 17,478 shares Expires 2032-06-07 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 8, 2023 or the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:40 UTC |
Vickers Philip J.Director
|
GrantStock Option (Right to Buy) · Derivative | 17,478 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001127602-22-017244 · form4.xml · derivative · entry 2 Vickers Philip J. · CIK 0001635046 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,478 Underlying: Common Stock · 17,478 shares Expires 2032-06-07 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 8, 2023 or the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:40 UTC |
Vickers Philip J.Director
|
GrantStock Option (Right to Buy) · Derivative | 17,478 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001127602-22-017244 · form4.xml · derivative · entry 1 Vickers Philip J. · CIK 0001635046 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,478 Underlying: Common Stock · 17,478 shares Expires 2032-06-07 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 8, 2023 or the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:36 UTC |
Booth BruceDirector
|
GrantStock Option (Right to Buy) · Derivative | 17,478 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001127602-22-017241 · form4.xml · derivative · entry 2 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,478 Underlying: Common Stock · 17,478 shares Expires 2032-06-07 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 8, 2023 or the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. F2 · ownership.direct: This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:36 UTC |
Booth BruceDirector
|
GrantStock Option (Right to Buy) · Derivative | 17,478 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001127602-22-017241 · form4.xml · derivative · entry 1 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,478 Underlying: Common Stock · 17,478 shares Expires 2032-06-07 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 8, 2023 or the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. F2 · ownership.direct: This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 16:43 UTC |
Donenberg Phillip B.Director
|
GrantStock Option (Right to Buy) · Derivative | 17,478 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001127602-22-017246 · form4.xml · derivative · entry 2 Donenberg Phillip B. · CIK 0001238120 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,478 Underlying: Common Stock · 17,478 shares Expires 2032-06-07 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 8, 2023 or the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 16:43 UTC |
Donenberg Phillip B.Director
|
GrantStock Option (Right to Buy) · Derivative | 17,478 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001127602-22-017246 · form4.xml · derivative · entry 1 Donenberg Phillip B. · CIK 0001238120 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,478 Underlying: Common Stock · 17,478 shares Expires 2032-06-07 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 8, 2023 or the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:41 UTC |
CLARK IAN TDirector
|
GrantStock Option (Right to Buy) · Derivative | 17,478 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001127602-22-017245 · form4.xml · derivative · entry 2 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,478 Underlying: Common Stock · 17,478 shares Expires 2032-06-07 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 8, 2023 or the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:41 UTC |
CLARK IAN TDirector
|
GrantStock Option (Right to Buy) · Derivative | 17,478 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001127602-22-017245 · form4.xml · derivative · entry 1 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,478 Underlying: Common Stock · 17,478 shares Expires 2032-06-07 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 8, 2023 or the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 16:39 UTC |
Farfel Gail MDirector
|
GrantStock Option (Right to Buy) · Derivative | 17,478 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001127602-22-017243 · form4.xml · derivative · entry 2 Farfel Gail M · CIK 0001614780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,478 Underlying: Common Stock · 17,478 shares Expires 2032-06-07 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 8, 2023 or the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 16:39 UTC |
Farfel Gail MDirector
|
GrantStock Option (Right to Buy) · Derivative | 17,478 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001127602-22-017243 · form4.xml · derivative · entry 1 Farfel Gail M · CIK 0001614780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,478 Underlying: Common Stock · 17,478 shares Expires 2032-06-07 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 8, 2023 or the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:38 UTC |
Jenkins AnnalisaDirector
|
GrantStock Option (Right to Buy) · Derivative | 17,478 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001127602-22-017242 · form4.xml · derivative · entry 2 Jenkins Annalisa · CIK 0001639481 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,478 Underlying: Common Stock · 17,478 shares Expires 2032-06-07 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 8, 2023 or the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:38 UTC |
Jenkins AnnalisaDirector
|
GrantStock Option (Right to Buy) · Derivative | 17,478 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001127602-22-017242 · form4.xml · derivative · entry 1 Jenkins Annalisa · CIK 0001639481 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,478 Underlying: Common Stock · 17,478 shares Expires 2032-06-07 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 8, 2023 or the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 17:24 UTC |
Petersen Deanna MChief Business Officer
|
GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $1.84 | $0.00 |
DisclosureSEC source: 0001127602-22-003428 · form4.xml · derivative · entry 2 Petersen Deanna M · CIK 0001493139 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: 25% of the shares shall vest and become exercisable on February 2, 2023, and the remaining 75% shall vest in equal monthly installments thereafter over a 3 year period. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 17:24 UTC |
Petersen Deanna MChief Business Officer
|
GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.84 | $0.00 |
DisclosureSEC source: 0001127602-22-003428 · form4.xml · derivative · entry 1 Petersen Deanna M · CIK 0001493139 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: 25% of the shares shall vest and become exercisable on February 2, 2023, and the remaining 75% shall vest in equal monthly installments thereafter over a 3 year period. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 22:22 UTC |
MACKAY GEOFFREYDirector · President & CEO
|
GrantStock Option (Right to Buy) · Derivative | 328,500 | $0.00 Strike: $1.84 | $0.00 |
DisclosureSEC source: 0001127602-22-003427 · form4.xml · derivative · entry 2 MACKAY GEOFFREY · CIK 0001741849 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,500 Underlying: Common Stock · 328,500 shares Expires 2032-02-01 F1 · derivative.exercise_date: 25% of the shares shall vest and become exercisable on February 2, 2023, and the remaining 75% shall vest in equal monthly installments thereafter over a 3 year period. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 22:22 UTC |
MACKAY GEOFFREYDirector · President & CEO
|
GrantStock Option (Right to Buy) · Derivative | 405,000 | $0.00 Strike: $1.84 | $0.00 |
DisclosureSEC source: 0001127602-22-003427 · form4.xml · derivative · entry 1 MACKAY GEOFFREY · CIK 0001741849 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,000 Underlying: Common Stock · 405,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: 25% of the shares shall vest and become exercisable on February 2, 2023, and the remaining 75% shall vest in equal monthly installments thereafter over a 3 year period. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 22:21 UTC |
Ridha EssraChief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $1.84 | $0.00 |
DisclosureSEC source: 0001127602-22-003426 · form4.xml · derivative · entry 2 Ridha Essra · CIK 0001888732 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: 25% of the shares shall vest and become exercisable on February 2, 2023, and the remaining 75% shall vest in equal monthly installments thereafter over a 3 year period. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 22:21 UTC |
Ridha EssraChief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.84 | $0.00 |
DisclosureSEC source: 0001127602-22-003426 · form4.xml · derivative · entry 1 Ridha Essra · CIK 0001888732 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: 25% of the shares shall vest and become exercisable on February 2, 2023, and the remaining 75% shall vest in equal monthly installments thereafter over a 3 year period. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 22:19 UTC |
Avruch StevenChief Legal Officer
|
GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $1.84 | $0.00 |
DisclosureSEC source: 0001127602-22-003424 · form4.xml · derivative · entry 2 Avruch Steven · CIK 0001762236 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: 25% of the shares shall vest and become exercisable on February 2, 2023, and the remaining 75% shall vest in equal monthly installments thereafter over a 3 year period. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 22:19 UTC |
Avruch StevenChief Legal Officer
|
GrantStock Option (Right to Buy) · Derivative | 105,000 | $0.00 Strike: $1.84 | $0.00 |
DisclosureSEC source: 0001127602-22-003424 · form4.xml · derivative · entry 1 Avruch Steven · CIK 0001762236 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: 25% of the shares shall vest and become exercisable on February 2, 2023, and the remaining 75% shall vest in equal monthly installments thereafter over a 3 year period. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 22:18 UTC |
Ostrowski ErikChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 145,000 | $0.00 Strike: $1.84 | $0.00 |
DisclosureSEC source: 0001127602-22-003423 · form4.xml · derivative · entry 2 Ostrowski Erik · CIK 0001762507 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 145,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: 25% of the shares shall vest and become exercisable on February 2, 2023, and the remaining 75% shall vest in equal monthly installments thereafter over a 3 year period. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 22:18 UTC |
Ostrowski ErikChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 170,000 | $0.00 Strike: $1.84 | $0.00 |
DisclosureSEC source: 0001127602-22-003423 · form4.xml · derivative · entry 1 Ostrowski Erik · CIK 0001762507 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 170,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: 25% of the shares shall vest and become exercisable on February 2, 2023, and the remaining 75% shall vest in equal monthly installments thereafter over a 3 year period. Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 20:59 UTC |
Ridha EssraChief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $5.67 | $0.00 |
DisclosureSEC source: 0001127602-21-028142 · form4.xml · derivative · entry 1 Ridha Essra · CIK 0001888732 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2031-10-31 F1 · derivative.exercise_date: 25% of the shares shall vest and become exercisable on November 1, 2022, and the remaining 75% shall vest in equal monthly installments thereafter over a 3 year period. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 20:21 UTC |
Vickers Philip J.Director
|
PurchaseCommon Stock | 4,800 | $8.35 | $40,080.00 |
DisclosureSEC source: 0001127602-21-021729 · form4.xml · nonDerivative · entry 1 Vickers Philip J. · CIK 0001635046 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,800 Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 17:55 UTC |
Escolar DianaChief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $9.63 | $0.00 |
DisclosureSEC source: 0001127602-21-019832 · form4.xml · derivative · entry 1 Escolar Diana · CIK 0001797269 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-06-09 F1 · derivative.exercise_date: 50% of the shares shall vest and become exercisable on June 10, 2023, and the remaining 50% shall vest and become exercisable on June 10, 2024. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 17:34 UTC |
PAIGE CHRISTOPHERDirector
|
GrantStock Option (Right to Buy) · Derivative | 17,438 | $0.00 Strike: $9.63 | $0.00 |
DisclosureSEC source: 0001127602-21-019818 · form4.xml · derivative · entry 1 PAIGE CHRISTOPHER · CIK 0001742209 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,438 Underlying: Common Stock · 17,438 shares Expires 2031-06-09 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 10, 2022 or the date of the Issuer's 2022 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 21:51 UTC |
Vickers Philip J.Director
|
GrantStock Option (Right to Buy) · Derivative | 17,438 | $0.00 Strike: $9.63 | $0.00 |
DisclosureSEC source: 0001127602-21-019828 · form4.xml · derivative · entry 1 Vickers Philip J. · CIK 0001635046 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,438 Underlying: Common Stock · 17,438 shares Expires 2031-06-09 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 10, 2022 or the date of the Issuer's 2022 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 18:06 UTC |
Petersen Deanna MChief Business Officer
|
GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $9.63 | $0.00 |
DisclosureSEC source: 0001127602-21-019840 · form4.xml · derivative · entry 1 Petersen Deanna M · CIK 0001493139 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2031-06-09 F1 · derivative.exercise_date: 50% of the shares shall vest and become exercisable on June 10, 2023, and the remaining 50% shall vest and become exercisable on June 10, 2024. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 21:32 UTC |
Booth BruceDirector
|
GrantStock Option (Right to Buy) · Derivative | 17,438 | $0.00 Strike: $9.63 | $0.00 |
DisclosureSEC source: 0001127602-21-019817 · form4.xml · derivative · entry 1 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,438 Underlying: Common Stock · 17,438 shares Expires 2031-06-09 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 10, 2022 or the date of the Issuer's 2022 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. F2 · ownership.direct: This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 17:04 UTC |
Donenberg Phillip B.Director
|
GrantStock Option (Right to Buy) · Derivative | 17,438 | $0.00 Strike: $9.63 | $0.00 |
DisclosureSEC source: 0001127602-21-019804 · form4.xml · derivative · entry 1 Donenberg Phillip B. · CIK 0001238120 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,438 Underlying: Common Stock · 17,438 shares Expires 2031-06-09 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 10, 2022 or the date of the Issuer's 2022 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 21:43 UTC |
CLARK IAN TDirector
|
GrantStock Option (Right to Buy) · Derivative | 17,438 | $0.00 Strike: $9.63 | $0.00 |
DisclosureSEC source: 0001127602-21-019822 · form4.xml · derivative · entry 1 CLARK IAN T · CIK 0001336504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,438 Underlying: Common Stock · 17,438 shares Expires 2031-06-09 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 10, 2022 or the date of the Issuer's 2022 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 17:47 UTC |
Farfel Gail MDirector
|
GrantStock Option (Right to Buy) · Derivative | 17,438 | $0.00 Strike: $9.63 | $0.00 |
DisclosureSEC source: 0001127602-21-019824 · form4.xml · derivative · entry 1 Farfel Gail M · CIK 0001614780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,438 Underlying: Common Stock · 17,438 shares Expires 2031-06-09 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 10, 2022 or the date of the Issuer's 2022 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 21:40 UTC |
Jenkins AnnalisaDirector
|
GrantStock Option (Right to Buy) · Derivative | 17,438 | $0.00 Strike: $9.63 | $0.00 |
DisclosureSEC source: 0001127602-21-019820 · form4.xml · derivative · entry 1 Jenkins Annalisa · CIK 0001639481 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,438 Underlying: Common Stock · 17,438 shares Expires 2031-06-09 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 10, 2022 or the date of the Issuer's 2022 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 22:03 UTC |
Mason ChristopherChief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $9.63 | $0.00 |
DisclosureSEC source: 0001127602-21-019838 · form4.xml · derivative · entry 1 Mason Christopher · CIK 0001836440 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2031-06-09 F1 · derivative.exercise_date: 50% of the shares shall vest and become exercisable on June 10, 2023, and the remaining 50% shall vest and become exercisable on June 10, 2024. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 21:59 UTC |
Ostrowski ErikChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $9.63 | $0.00 |
DisclosureSEC source: 0001127602-21-019836 · form4.xml · derivative · entry 1 Ostrowski Erik · CIK 0001762507 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2031-06-09 F1 · derivative.exercise_date: 50% of the shares shall vest and become exercisable on June 10, 2023, and the remaining 50% shall vest and become exercisable on June 10, 2024. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 21:58 UTC |
MACKAY GEOFFREYDirector · President & CEO
|
GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $9.63 | $0.00 |
DisclosureSEC source: 0001127602-21-019834 · form4.xml · derivative · entry 1 MACKAY GEOFFREY · CIK 0001741849 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2031-06-09 F1 · derivative.exercise_date: 50% of the shares shall vest and become exercisable on June 10, 2023, and the remaining 50% shall vest and become exercisable on June 10, 2024. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 21:53 UTC |
Avruch StevenChief Legal Officer
|
GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $9.63 | $0.00 |
DisclosureSEC source: 0001127602-21-019830 · form4.xml · derivative · entry 1 Avruch Steven · CIK 0001762236 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2031-06-09 F1 · derivative.exercise_date: 50% of the shares shall vest and become exercisable on June 10, 2023, and the remaining 50% shall vest and become exercisable on June 10, 2024. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 19:06 UTC |
Donenberg Phillip B.Director
|
PurchaseCommon Stock | 2,000 | $11.71 | $23,420.00 |
DisclosureSEC source: 0001127602-21-006556 · form4.xml · nonDerivative · entry 1 Donenberg Phillip B. · CIK 0001238120 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Read SEC document |
| February 04, 2021 Filed Feb 4, 2021 17:53 UTC |
Petersen Deanna MChief Business Officer
|
GrantStock Option (Right to Buy) · Derivative | 86,600 | $0.00 Strike: $16.02 | $0.00 |
DisclosureSEC source: 0001127602-21-004041 · form4.xml · derivative · entry 1 Petersen Deanna M · CIK 0001493139 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,600 Underlying: Common Stock · 86,600 shares Expires 2031-02-03 F1 · derivative.exercise_date: 25% of the shares shall vest and become exercisable on February 4, 2022, and the remaining 75% shall vest in equal monthly installments thereafter over a 3 year period. Read SEC document |
| February 04, 2021 Filed Feb 4, 2021 22:56 UTC |
MACKAY GEOFFREYDirector · President & CEO
|
GrantStock Option (Right to Buy) · Derivative | 343,850 | $0.00 Strike: $16.02 | $0.00 |
DisclosureSEC source: 0001127602-21-004043 · form4.xml · derivative · entry 1 MACKAY GEOFFREY · CIK 0001741849 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,850 Underlying: Common Stock · 343,850 shares Expires 2031-02-03 F1 · derivative.exercise_date: 25% of the shares shall vest and become exercisable on February 4, 2022, and the remaining 75% shall vest in equal monthly installments thereafter over a 3 year period. Read SEC document |
| February 04, 2021 Filed Feb 4, 2021 22:55 UTC |
Avruch StevenChief Legal Officer
|
GrantStock Option (Right to Buy) · Derivative | 98,200 | $0.00 Strike: $16.02 | $0.00 |
DisclosureSEC source: 0001127602-21-004042 · form4.xml · derivative · entry 1 Avruch Steven · CIK 0001762236 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,200 Underlying: Common Stock · 98,200 shares Expires 2031-02-03 F1 · derivative.exercise_date: 25% of the shares shall vest and become exercisable on February 4, 2022, and the remaining 75% shall vest in equal monthly installments thereafter over a 3 year period. Read SEC document |
| February 04, 2021 Filed Feb 4, 2021 22:51 UTC |
Ostrowski ErikChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 119,100 | $0.00 Strike: $16.02 | $0.00 |
DisclosureSEC source: 0001127602-21-004040 · form4.xml · derivative · entry 1 Ostrowski Erik · CIK 0001762507 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,100 Underlying: Common Stock · 119,100 shares Expires 2031-02-03 F1 · derivative.exercise_date: 25% of the shares shall vest and become exercisable on February 4, 2022, and the remaining 75% shall vest in equal monthly installments thereafter over a 3 year period. Read SEC document |
| February 01, 2021 Filed Feb 2, 2021 16:55 UTC |
Escolar DianaChief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 130,000 | $0.00 Strike: $14.55 | $0.00 |
DisclosureSEC source: 0001127602-21-003526 · form4.xml · derivative · entry 1 Escolar Diana · CIK 0001797269 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2031-01-31 F1 · derivative.exercise_date: 25% of the shares shall vest and become exercisable on February 1, 2022, and the remaining 75% shall vest in equal monthly installments thereafter over a 3 year period. Read SEC document |
| December 24, 2020 Filed Dec 29, 2020 00:46 UTC |
MACKAY GEOFFREYDirector · President & CEO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.41 | $0.00 |
DisclosureSEC source: 0001127602-20-032415 · form4.xml · derivative · entry 5 MACKAY GEOFFREY · CIK 0001741849 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,013 Underlying: Common Stock · 100,000 shares Expires 2026-04-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This filing relates to the exercise of a Stock Option. No shares of Common Stock were sold by the Reporting Person, and the shares of Common Stock received upon exercise of the Stock Option are subject to a lock-up agreement with Morgan Stanley & Co. LLC and Cowen and Company, LLC. F2 · derivative.exercise_date: 25% of the shares vested on July 1, 2017, and the remaining 75% vest in equal quarterly installments thereafter over a three-year period. Read SEC document |
| December 24, 2020 Filed Dec 29, 2020 00:46 UTC |
MACKAY GEOFFREYDirector · President & CEO
|
Exercise / conversionCommon Stock | 100,000 | $0.41 | $41,320.00 |
DisclosureSEC source: 0001127602-20-032415 · form4.xml · nonDerivative · entry 1 MACKAY GEOFFREY · CIK 0001741849 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,123 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This filing relates to the exercise of a Stock Option. No shares of Common Stock were sold by the Reporting Person, and the shares of Common Stock received upon exercise of the Stock Option are subject to a lock-up agreement with Morgan Stanley & Co. LLC and Cowen and Company, LLC. Read SEC document |
| October 19, 2020 Filed Oct 21, 2020 16:24 UTC |
Farfel Gail MDirector
|
GrantStock Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $16.14 | $0.00 |
DisclosureSEC source: 0001127602-20-027388 · form4.xml · derivative · entry 1 Farfel Gail M · CIK 0001614780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2030-10-18 F1 · derivative.exercise_date: The Stock Option shall vest and become exercisable in 36 equal monthly installments over a three-year period. Read SEC document |
| June 04, 2020 Filed Jun 5, 2020 17:06 UTC |
PAIGE CHRISTOPHERDirector
|
GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $21.91 | $0.00 |
DisclosureSEC source: 0001127602-20-019012 · form4.xml · derivative · entry 1 PAIGE CHRISTOPHER · CIK 0001742209 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2030-06-03 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 4, 2021 or the date of the Issuer's 2021 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document |
| June 04, 2020 Filed Jun 5, 2020 21:09 UTC |
Vickers Philip J.Director
|
GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $21.91 | $0.00 |
DisclosureSEC source: 0001127602-20-019015 · form4.xml · derivative · entry 1 Vickers Philip J. · CIK 0001635046 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2030-06-03 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 4, 2021 or the date of the Issuer's 2021 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document |
| June 04, 2020 Filed Jun 5, 2020 21:18 UTC |
Booth BruceDirector
|
GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $21.91 | $0.00 |
DisclosureSEC source: 0001127602-20-019028 · form4.xml · derivative · entry 1 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2030-06-03 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 4, 2021 or the date of the Issuer's 2021 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. F2 · ownership.direct: This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.